anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Norman architecture typically stands out as a new stage in the architectural history of the regions they subdued. They spread a unique Romanesque idiom to England, Italy and Ireland, and the encastellation of these regions with keeps in their north French style fundamentally altered the military landscape. Their style was characterised by rounded arches, particularly over windows and doorways, and massive proportions. In England, the period of Norman architecture immediately succeeds that of the Anglo-Saxon and precedes the Early Gothic. In southern Italy, the Normans incorporated elements of Islamic, Lombard, and Byzantine building techniques into their own, initiating a unique romanesque style known as Norman-Arab architecture within the Kingdom of Sicily and precedes the Early Gothic.
Selenium has bimodal biological action depending on the concentration. At low nutritional doses, selenium acts as an antioxidant through selenoproteins, scavenging ROS, supporting cell survival and growth; while, at supra-nutritional higher pharmacological doses, selenium acts as a pro-oxidant generating ROS and inducing cell death. In cancer, studies have been conducted mostly on the benefits of selenium intake in reducing the risk of cancer incidence at the nutritional level; however, fewer studies have explored the effects of supra-nutritional or pharmacological doses of selenium on cancer. "Although an inverse association between selenium exposure and the risk of some types of cancer was found in some observational studies, this cannot be taken as evidence of a causal relation, and these results should be interpreted with caution... Conflicting results including inverse, null and direct associations have been reported for some cancer types... RCTs assessing the effects of selenium supplementation on cancer risk have yielded inconsistent results... To date, no convincing evidence suggests that selenium supplements can prevent cancer in humans."
==== Antidepressants ==== Some antidepressants have hypnotic and/or sedative effects. These include the serotonin antagonist and reuptake inhibitor (SARI) trazodone, tricyclic antidepressants (TCAs) such as amitriptyline, doxepin, and trimipramine, and tetracyclic antidepressants (TeCAs) like mirtazapine and mianserin. These agents produce their hypnotic and sedative effects via multiple mechanisms of action that may include histamine H1 receptor antagonism, serotonin 5-HT2A receptor antagonism, and α1-adrenergic receptor antagonism. Some hypnotic antidepressants, such as trazodone and mirtazapine, have been shown to enhance slow wave sleep, which may be due to serotonin 5-HT2A receptor antagonism.
== Mechanism of action == Tyrocidine has a unique mode of action in which it disrupts the cell membrane function, making it a favorable target for engineering derivatives. Tyrocidine appears to perturb the lipid bilayer of a microbe's inner membrane by permeating the lipid phase of the membrane. The exact affinity and location of tyrocidine within the phospholipid bilayer is not yet known.
This helps reduce the potential for deviating from the prescriber's intended use relative to buprenorphine, though it does not eradicate it. One reason that naloxone might have limited efficacy as an abuse-deterrent is that buprenorphine binds more tightly to the mu-opioid receptor than naloxone.
Sources: en.wikipedia.org
=== Plant screening program === In 1955, the NCI in the United States set up the Cancer Chemotherapy National Service Center (CCNSC) to act as a public screening center for anticancer activity in compounds submitted by external institutions and companies. Although the majority of compounds screened were of synthetic origin, one chemist, Jonathan Hartwell, who was employed there from 1958 onwards, had experience with natural product derived compounds, and began a plant screening operation. After some years of informal arrangements, in July 1960, the NCI commissioned the United States Department of Agriculture (USDA) botanists to collect samples from about 1,000 plant species per year. On 21 August 1962, one of those botanists, Arthur S. Barclay, collected bark from a single Pacific yew tree in a forest north of the town of Packwood, Washington, as part of a four-month trip to collect material from over 200 different species. The material was then processed by a number of specialist CCNSC subcontractors, and one of the tree's samples was found to be cytotoxic in a cellular assay on 22 May 1964. Accordingly, in late 1964 or early 1965, the fractionation and isolation laboratory run by Monroe E. Wall in Research Triangle Park, North Carolina, began work on fresh Taxus samples, isolating the active ingredient in September 1966 and announcing their findings at an April 1967 American Chemical Society meeting in Miami Beach. They named the pure compound taxol in June 1967. Wall and his colleague Wani published their results, including the chemical structure, in 1971.
Placing workers at the heart of changes made, including through workers being placed on company boards The implementation of a "right to disconnect" to prevent AI-enabled remote working from creating an "always-on" culture. Attaching "good work" conditions to public funding for AI research and development. The TUC has also drafted a model Artificial Intelligence (Regulation and Employment Rights) Bill, designed to fill the regulatory gap left by the UK's divergence from EU data protection standards and the absence of a domestic equivalent to the EU AI Act. Prospect, the union representing scientists, engineers, and tech workers, has campaigned for civil servants and technical professionals to have a voice in the rollout of AI. Prospect has highlighted the risks of an "always-on" culture, of the prevalence of workplace surveillance, and the need for workers to have ownership over the data collected about them by their employers.
==== Central nervous system ==== The central nervous system (CNS) consists of a bilobed brain (cerebral ganglia, or supra-pharyngeal ganglion), sub-pharyngeal ganglia, circum-pharyngeal connectives and a ventral nerve cord. Earthworms' brains consist of a pair of pear-shaped cerebral ganglia. These are located in the dorsal side of the alimentary canal in the third segment, in a groove between the buccal cavity and pharynx. A pair of circum-pharyngeal connectives from the brain encircle the pharynx and then connect with a pair of sub-pharyngeal ganglia located below the pharynx in the fourth segment. This arrangement means the brain, sub-pharyngeal ganglia and the circum-pharyngeal connectives form a nerve ring around the pharynx. The ventral nerve cord (formed by nerve cells and nerve fibers) begins at the sub-pharyngeal ganglia and extends below the alimentary canal to the most posterior body segment. The ventral nerve cord has a swelling, or ganglion, in each segment, i.e. a segmental ganglion, which occurs from the fifth to the last segment of the body. There are also three giant axons, one medial giant axon (MGA) and two lateral giant axons (LGAs) on the mid-dorsal side of the ventral nerve cord. The MGA is 0.07 mm in diameter and transmits in an anterior-posterior direction at a rate of 32.2 m/s. The LGAs are slightly narrower at 0.05 mm in diameter and transmit in a posterior-anterior direction at 12.6 m/s. The two LGAs are connected at regular intervals along the body and are therefore considered one giant axon.
=== Pyrosequencing === Similar to its use in direct Sanger sequencing, with pyrosequencing COLD-PCR was shown to be capable of detecting mutations that had a prevalence 0.5–1% from the samples used. COLD-PCR was used to detect p53 and KRAS mutations by pyrosequencing, and was shown to outperform conventional PCR in both cases.
=== Measuring methods for contents of cannabinoids === Measuring methods for cannabinoids are based on the extraction of fluids from the hemp plant. Research and studies conducted at the University of Wuppertal (Germany) have shown that extracts contain much less of the initial contents of the hemp plant present in the juice. Besides, with extracts there is a risk of residues of solvents. There are no specific measuring methods for the quantities of cannabinoids in hemp juice accepted by all states. The EU is working on the development of a commonly accepted procedure. An alternative procedure used for the extraction of fluids first filters and centrifuges the hemp juice. The findings however showed no traces of cannabinoids because the characteristic contents of the hemp plant solely can be found in the unfiltered hemp juice.
Sources: en.wikipedia.org
1986 Reliability theory of aging and longevity proposed by Leonid Gavrilov and Natalia Gavrilova. At first it was published only in the USSR. In English language the theory was published five years later, in 1991. 1990 Formation of the Gerontology Research Group (GRG) which searches for supercentenarians around the world and verifies their age. Whenever possible, the organization tries to collect data on why these people live significantly longer than the average person. The organization regularly publishes a list of the oldest verified living supercentenarians. 1992 National Archive of Computerized Data on Aging (NACDA) published in the Internet the first 28 datasets related to aging. Gradually the number of published datasets has grown to over 1600 and continues to grow. These datasets are available to any researcher around the world at no charge, so they can search in them for new patterns. The site also provides some tools to facilitate analysis. 1993 Cynthia Kenyon and Ramon Tabtiang doubled the lifespan of C. elegans nematodes by partially disabling a gene, with the nematodes remaining relatively healthy for significantly longer. The discovery was a revolutionary breakthrough in aging research, demonstrating that the aging process could be controlled in the laboratory, and sparked more research into the molecular biology of aging. 1995 Method for detection of senescent cells using a cytochemical assay. 1997 The absolute record for the duration of human life. The French woman Jeanne Calment lived 122 years and 164 days (the record is still held).
Yasmin Kara-Hanani (Marisa Abela) is a graduate recruit on Pierpoint’s Foreign Exchange (FX) Sales desk and one of the series’ protagonists. A wealthy heiress to the Hanani Publishing empire and fluent in multiple languages, she is materially privileged but emotionally unstable, with deeply strained relationships to her divorced parents—particularly her manipulative, philandering father Charles. In series 1, Yasmin works under Vice President (VP) Kenny Kilbane, who repeatedly subjects her to bullying and verbal abuse. She lives alone in her father’s Notting Hill apartment, ends an unsatisfying relationship with her boyfriend Seb, and begins aggressively flirting with Robert Spearing, enjoying her emotional leverage over him despite his growing attachment. She befriends Harper Stern, who becomes her flatmate, though their friendship is complicated by Harper’s unreciprocated feelings for Robert and workplace rivalries. Despite Kenny’s conduct, Hilary Wyndham, Managing Director (MD) at the FX desk and Kenny's superior, advises Yasmin to remain silent during her Reduction in Force (RIF) day interview to appear a “team player.” Yasmin complies and is hired full-time, but Harper’s decision to reinstate Eric Tao and sacrifice Daria Greenock damages their friendship. In series 2, Yasmin grows more competent and assertive on the desk while remaining hostile toward Harper. Kenny returns from rehab seeking absolution, which Yasmin refuses. She begins a sexual relationship with private wealth manager Celeste Pacquet and angles for a move into PWM.
=== Cleaning and sterilization === Sterilization is a standard practice to prevent development of bacteria and resulting illness, that is more effective than sanitization. The Australian government and the United Kingdom's National Health Service guidelines recommend sterilization of baby bottles and other equipment either by using a cold water sterilizing solution such as by Milton sterilizing fluid, by steam sterilizing, or by boiling. It is important to clean and sterilize all parts of a bottle including containers, teats, and screw caps. The United States Centers for Disease Control and Prevention, suggests that it may be sufficient to clean bottles with soap and water, in a dishwasher or by hand. This recommendation is based on the assumption that water supplies are clean and sanitation standards are high. Some states, such as Illinois, continue to recommend sterilization in addition to washing. Alberta, Canada recommends sterilizing bottles that are used with formula until an infant is at least 4 months old. However, there is evidence that bacteria such as E. coli can thrive in biofilms which form on the interior walls of the bottles. Gentle rinsing is not enough to prevent this. Even in developed areas, contamination continues to be a concern. In 2009 in the United Kingdom, researchers found contamination with Staphylococcus aureus in 4% of the baby bottles that parents reported were ready to fill after cleaning and disinfecting. In lower-resource settings, risks of exposure to dangerous respiratory and enteric infections are higher.
Aprataxin is 342 amino acids long and consists of FHA domain and HIT-ZnF catalyc core. It works by binding to adenylated DNA and removing AMP by catalytic side. Aprataxin is localised in the nucleus and mitochondria, which means aprataxin participates in mitochondrial DNA repair. This protein participates in base excision repair (BER) by returning abortive DNA ligation into scheduled repair by DNA polymerase beta, which would remove 5'-deoxyribosephosphate residue (dRP) and fill the gap; consequently, DNA ligase III-XRCC1 complex would seal the gap; consequently this mechanism is hampered in AOA1. Also, it might participate in microhomology-mediated end joining (MMEJ) by associating with XRCC1 and DNA ligase III and safeguarding DNA from abortive ligations by DNA ligase I, which might, again, be hampered in AOA1. iPSC with AOA1-associated mutation showed hindered differentiation into neurons which could be responsinble for early onset. Additionally, these neurons showed increased levels of cleaved PARP1 and decreased levels of APEX1. Due to the unique structure of chromatin in Purkinje cells, DNA damage (caused by aprataxin dysfunction) would hamper RNA polymerase II function, which would lead to improper splicing of some genes (such as: ITPR1, GRID2, CA8) and consequeent formation of R-loops; R-loops can exacerbate DNA damage. Because of dysregulation of genes, this would lead to ataxia. Decreased levels of albumin and elevated alpha-fetoprotein in AOA1 might be caused by transcriptional dysregulation in the liver.
=== Early life and education === Martin Litchfield West was born on 23 September 1937 at Eltham General Hospital (Eltham, London), the elder child (there being a younger daughter, Dr Jennifer Bywaters) of civil engineer Maurice Charles West and Catherine Baker, née Stainthorpe. His parents lived at that time in Orpington, but moved in 1939 to Hampton, where his father was appointed resident engineer at the Metropolitan Water Board-operated waterworks. West's father's family were from the Home Counties, and his mother's family from Yorkshire and Durham. His paternal grandfather, Robert West, lectured in electrical engineering; his maternal grandfather, John Stainthorpe, was a railwayman from Pickering. Litchfield was the maiden name of his paternal grandmother. Aged four, West entered the private preparatory school of Denmead. At 11, he lost a scholarship at Colet Court (now St Paul's Juniors), but was offered a feepaying place instead. West discovered at Colet his interest in languages and invented at 14 a competitor of Esperanto he labelled 'Unilingua'. In 1951, he won a scholarship to the main school, St Paul's. Excelling at both linguistics and mathematics, he was advanced to the 'Upper Eighth' and sat for a scholarship to Balliol College a year early. His tutors included Donald Russell, Michael Stokes and Russell Meiggs. Among his peers were future Nobel Prize winner Anthony J. Leggett, and future Permanent Secretary Peter Gregson.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.